Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

Study identifies risk factors for severe CoviD-19 in children.

15 Feb, 2022 | 10:01h | UTC

Risk Factors for Severe COVID-19 in Children – Pediatrics

 

Covid-19: Fourth vaccine doses—who needs them and why?

15 Feb, 2022 | 09:59h | UTC

Covid-19: Fourth vaccine doses—who needs them and why? – The BMJ

 

Pfizer and FDA pull back from plan to expedite review of Covid-19 vaccine in children under 5.

13 Feb, 2022 | 22:51h | UTC

Pfizer and FDA pull back from plan to expedite review of Covid-19 vaccine in young children – STAT

See also:

COVID-19 vaccine for kids under 5 delayed as Pfizer extends trial – CIDRAP

Pfizer postpones FDA request for Covid vaccine for kids under 5 – NBC News

 

Novavax says protein vaccine works for kids as young as 12.

13 Feb, 2022 | 22:54h | UTC

Novavax says protein vaccine works for kids as young as 12 – Associated Press

Press Release: Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial

Related:

Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.

RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths.

Opinion | The mRNA vaccines are extraordinary, but Novavax is even better.

(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant

New COVID-19 vaccines: here’s how the promising Novavax and Johnson & Johnson jabs work

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

 

Covid-19: What do we know about omicron sublineages?

13 Feb, 2022 | 22:42h | UTC

Covid-19: What do we know about omicron sublineages? – The BMJ

Related:

We regret to inform you that we are now discussing subvariants – Vox

Sudden rise of more transmissible form of Omicron catches scientists by surprise.

Omicron’s sister variant spreads faster. So why did the one we call Omicron hit first?

[Preprint] Study suggests SARS-CoV-2 Omicron subvariants BA.2 is even more transmissible than the original variant.

BA.2 is like Omicron’s sister. Here’s what we know about it so far – The Conversation

 

Commentary on Twitter

 

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant.

13 Feb, 2022 | 22:49h | UTC

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant – STAT

Related:

FDA halts use of antibody drugs that don’t work vs. Omicron.

Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

 

ERS statement on Long COVID-19 follow-up.

13 Feb, 2022 | 22:48h | UTC

European Respiratory Society Statement on Long COVID-19 Follow-Up – European Respiratory Review

 

First research definition for ‘Long COVID’ in kids and young people formally agreed.

13 Feb, 2022 | 22:45h | UTC

News Release: First research definition for ‘Long COVID’ in kids and young people formally agreed – BMJ

Original Article (preprint): Long COVID (Post-COVID-19 condition) in Children: a modified Delphi Process – Archives of Disease in Childhood

Commentaries:

Expert reaction to Delphi consensus study on a long-COVID definition in children – Science Media Centre

Long covid: “Holistic” approach is best, given range of symptoms, say researchers – The BMJ

Related:

Cohort Study: Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England.

A nationwide cohort study in Denmark showed Long Covid in children is rare and mainly of short duration.

Editorial | Long covid in children and adolescents – “Risk appears low, but many questions remain”.

M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

 

Special Issue: Evidence-based strategies for better antibiotic prescribing in primary care.

13 Feb, 2022 | 22:40h | UTC

Editorial: Antibiotic stewardship – Australian Journal of General Practice

Antibiotic stewardship: A review of successful, evidence-based primary care strategies – Australian Journal of General Practice

Evidence-based strategies for better antibiotic prescribing – Australian Journal of General Practice

How can general practitioners reduce antibiotic prescribing in collaboration with their patients? – Australian Journal of General Practice

 

RCT: Primary Norfloxacin prophylaxis prevents bacterial infections in patients with acute-on-chronic liver failure.

13 Feb, 2022 | 22:37h | UTC

Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial – The American Journal of Gastroenterology (link to abstract – $ for full-text)

 

Guideline for the management Herpes Simplex 1 and cosmetic interventions.

13 Feb, 2022 | 21:41h | UTC

Guideline for the Management Herpes Simplex 1 and Cosmetic Interventions – The Journal of Clinical and Aesthetic Dermatology

 

Guideline for the prevention, diagnosis, and management of acute bacterial soft tissue infections following nonsurgical cosmetic procedures.

13 Feb, 2022 | 21:40h | UTC

Guideline for the Prevention, Diagnosis, and Management of Acute Bacterial Soft Tissue Infections Following Nonsurgical Cosmetic Procedures – The Journal of Clinical and Aesthetic Dermatology

 

IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections.

11 Feb, 2022 | 08:51h | UTC

IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections – Clinical Microbiology and Infection

Original Guidelines:

European guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli.

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

 

Babies born during pandemic’s first year score slightly lower on a developmental screening test.

11 Feb, 2022 | 08:46h | UTC

News Release: Babies born during pandemic’s first year score slightly lower on a developmental screening test – Columbia University Irving Medical Center

Original Study: Association of Birth During the COVID-19 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In Utero Exposure to Maternal SARS-CoV-2 Infection – JAMA Pediatrics

Editorial: Understanding the Effects of the Pandemic on Infant Development—The Preterm Problem

Commentaries:

Covid-19: Babies born during the pandemic show slight development delays – The BMJ

Pandemic birth tied to poor development – CIDRAP

 

Audio Interview: Covid-19 as an endemic disease.

11 Feb, 2022 | 08:47h | UTC

Audio Interview: Covid-19 as an Endemic Disease – New England Journal of Medicine

 

Community control strategies for scabies: A cluster randomized trial showed one dose of Ivermectin was noninferior to two doses (7 to 14 days apart) to reduce the prevalence of the disease at 12 months.

11 Feb, 2022 | 08:38h | UTC

Community control strategies for scabies: A cluster randomised noninferiority trial – PLOS Medicine

News Release: One dose of anti-parasite drug just as effective as two at reducing scabies – Murdoch Children’s Research Institute

 

Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection.

11 Feb, 2022 | 08:44h | UTC

Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection – European Respiratory Review

 

Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments.

11 Feb, 2022 | 08:29h | UTC

Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments – European Respiratory Review

 

M-A: In patients undergoing transperineal prostate biopsy, there was no significant difference in infection, fever, sepsis or readmission rates with vs. without the use of prophylactic antibiotics.

11 Feb, 2022 | 08:16h | UTC

Infection Rate after Transperineal Prostate Biopsy with and without Prophylactic Antibiotics: Results from a Systematic Review and Meta-Analysis of Comparative Studies – Journal of Urology

 

Sweden ends COVID-19 testing as pandemic restrictions lifted – “only health care and elderly care workers and the most vulnerable will be entitled to free PCR testing if they are symptomatic, while the rest of the population will simply be asked to stay home if they show symptoms that could be COVID-19”.

10 Feb, 2022 | 10:07h | UTC

Sweden ends COVID-19 testing as pandemic restrictions lifted – Associated Press

Related:

How Denmark Decided COVID Isn’t a Critical Threat to Society – “The country became the first in the EU to lift all COVID restrictions despite leading the world in per capita infections”.

Covid: Europe set for ‘long period of tranquillity’ in pandemic, says WHO.

As Denmark scraps COVID restrictions, WHO urges caution.

Despite the ongoing spread of Omicron, some European countries have decided to lift Covid-19 restrictions.

 

Clinical practice guideline on tympanostomy tubes in children.

10 Feb, 2022 | 10:10h | UTC

Executive Summary of Clinical Practice Guideline on Tympanostomy Tubes in Children (Update) – Otolaryngology–Head and Neck Surgery

 

A population-based study in Qatar showed previous infection provided robust protection against reinfection with the alpha, beta, and delta variants of SARS-CoV-2 (approximately 90%). However, protection against reinfection with the omicron variant was lower (around 60%).

10 Feb, 2022 | 10:04h | UTC

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection – New England Journal of Medicine

 

Commentary on Twitter

 

RCT: Final analysis of efficacy and safety of single-dose J&J vaccine.

10 Feb, 2022 | 10:03h | UTC

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S – New England Journal of Medicine

 

Commentary on Twitter

 

Vaccine effectiveness of heterologous CoronaVac plus Pfizer in Brazil.

10 Feb, 2022 | 10:01h | UTC

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil – Nature Medicine

 

Commentary on Twitter

 

IDSA Updated Covid-19 Guideline now supports the use of convalescent plasma in ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease.

9 Feb, 2022 | 10:15h | UTC

IDSA Guidelines on the Treatment and Management of Patients with COVID-19 – Infectious Diseases Society of America

Related: [Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations.

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.